We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Crush Stenting With Paclitaxel-Eluting or Sirolimus-Eluting Stents for the Treatment of Coronary Bifurcation Lesions.
- Authors
Shaoliang Chen; Junjie Zhang; Fei Ye; Zhongsheng Zhu; Song Lin; Nailiang Tian; Zhizhong Liu; Weiyi Fang; Yundai Chen; Xuewen Sun; Kwan, Tak W.
- Abstract
Two hundred forty-six patients with 252 bifurcation lesions were enrolled into a prospective, nonrandomized study to use paclitaxel-eluting or sirolimus-eluting stent for crush stenting in the treatment of coronary bifurcation lesions. Compared with the sirolimus-eluting stent group, the paclitaxel-eluting stent group had significantly higher mean late lumen and binary angiographic restenosis rates. Sirolimus-eluting stent versus paclitaxel-eluting stent recipients had significantly lower in-segment restenosis in the entire main vessel (15.7% vs 3.1%, P = .004), and simultaneous side branch and main vessel restenoses were solely detected in the paclitaxel-eluting stent group (11.9% vs 0%, P = .03). Target-lesion vessel revascularization and cumulative major adverse cardiac events rates were significantly higher in the paclitaxel-eluting versus the sirolimus-eluting stent group (17.99% vs 8.41%, P = .01; 19.4 vs 9.3%, P = .01; 23.6 vs 11.2%, P = .03). In this study with crush stenting, use of sirolimus-eluting stent, compared with paclitaxel-eluting stent, yielded significantly lower late lumen loss, restenosis, and revascularization rates, with comparable safety by 8-month follow-up.
- Subjects
HEART diseases; THERAPEUTICS; SURGICAL stents; PACLITAXEL; RAPAMYCIN; MYOCARDIAL revascularization
- Publication
Angiology, 2008, Vol 59, Issue 4, p475
- ISSN
0003-3197
- Publication type
Article
- DOI
10.1177/0003319707312519